Lead Product(s) : ASC30
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ascletis Reports Positive Phase Ib Results for Oral GLP-1R Agonist ASC30
Details : ASC30 is an investigational GLP-1R biased small molecule agonist and has unique and differentiated properties that enable the same small molecule for both oral tablet and subcutaneous injection.
Product Name : ASC30
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 22, 2025
Lead Product(s) : ASC30
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ASC30
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30
Details : ASC30 is an investigational small-molecule agonist biased toward GLP-1R. It is being evaluated as a once-daily oral tablet for the treatment of obesity.
Product Name : ASC30
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 31, 2025
Lead Product(s) : ASC30
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ASC30
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ascletis Announces Positive Phase Ib Study of Small Molecule Oral GLP-1R Agonist ASC30
Details : ASC30 is an investigational small-molecule agonist biased toward GLP-1R. It is being evaluated as a once-daily oral tablet for the treatment of obesity.
Product Name : ASC30
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 19, 2025
Lead Product(s) : ASC30
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ASC30
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ascletis' GLP-1R Agonist ASC30 Shows Positive Phase Ia Results
Details : ASC30 is the first and only small molecule GLP-1 receptor (GLP-1R) agonist that can be dosed once-monthly subcutaneously and once-daily orally for the treatment of obesity.
Product Name : ASC30
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 21, 2025
Lead Product(s) : ASC30
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ecnoglutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Verdiva Bio
Deal Size : $2,470.0 million
Deal Type : Licensing Agreement
Sciwind Biosciences Signs Licensing Agreement for Metabolic Disease Portfolio
Details : Under the licensing agreement, Sciwind has granted Verdiva the exclusive global rights to develop and commercialize the partnered programs, which includes XW004 (ecnoglutide) outside of greater China.
Product Name : XW004
Product Type : Peptide
Upfront Cash : $70.0 million
January 10, 2025
Lead Product(s) : Ecnoglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Verdiva Bio
Deal Size : $2,470.0 million
Deal Type : Licensing Agreement
Lead Product(s) : ASC47,Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ascletis Announces ASC47 + Semaglutide Shows Superior Weight Loss in Preclinical
Details : ASC47 is an adipose-targeted thyroid hormone receptor beta (THRβ) selective small molecule agonist. It is being evaluated in combination with semaglutide for the treatment of obesity.
Product Name : ASC47
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 18, 2024
Lead Product(s) : ASC47,Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LAE102
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Collaboration
China-Based Biotech Laekna Teams up with Lilly to Develop Muscle Preserving Obesity Drug
Details : The collaboration will accelerate the global development of LAE102, a novel Activin Receptor Type 2 A (ActRIIA) antagonistic monoclonal antibody (mAb) for muscle-preserving weight loss in Obesity.
Product Name : LAE102
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
November 20, 2024
Lead Product(s) : LAE102
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : ASC30
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ascletis Begins Phase I Trials for Obesity GLP-1R Agonist ASC30
Details : ASC30 is an investigational small-molecule agonist biased toward GLP-1R. It is being evaluated as a once-daily oral tablet for the treatment of obesity.
Product Name : ASC30
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 17, 2024
Lead Product(s) : ASC30
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ASC47
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ascletis Reports Promising Phase 1 Results for ASC47 in Obesity Treatment
Details : ASC47 is an adipose-targeted thyroid hormone receptor beta (THRβ) selective small molecule agonist. It is being evaluated for the treatment of obesity.
Product Name : ASC47
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 11, 2024
Lead Product(s) : ASC47
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DR10624
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zhejiang Doer Completes Phase 1b/2a Trial Enrollment for DR10624 in Obese Subjects
Details : DR10624 is a novel FIC tri-specific biotherapeutic that specifically agonizing GLP-1R, glucagon receptor GCGR & FGF21R, it is being investigated for the treatment of obesity and hypertriglyceridemia.
Product Name : DR10624
Product Type : Protein
Upfront Cash : Inapplicable
May 07, 2024
Lead Product(s) : DR10624
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable